Fully-Automated Chemiluminescence Analyzer Enables Fast, Convenient Testing in Clinical and Emergency Settings

Furthermore, the constant rise in the standards for test performance and result accuracy is driving advancements in in-vitro diagnostic (IVD) test platforms. Now, a strategic partnership has now further expanded the range of diagnostic solutions available for laboratories in China by offering a fully automated chemiluminescence immunoassay (CLIA) analyzer along with compatible assay kits to serve the region's patient community.

Roche Diagnostics China (Basel, Switzerland) is the exclusive agent in mainland China of RealMind Biotech’s (Nanjing, China) MCL60 CLIA analyzer, along with its matching chemiluminescence assay kits (including cardiac biomarkers, inflammatory biomarkers, sexual hormones, thyroid function, stomach function, etc.). The MCL60 bench-top CLIA system employs direct CLIA with acridinium ester (AE) label and is compatible with various sample types, such as capillary blood, whole blood, serum, and plasma. The MCL60 is fully automated with a throughput of up to 144 tests/hour, and the first result is available in 13 minutes. It fulfills the clinical requirements for flexible, convenient, precise, and efficient testing, and is applicable in a wide range of departments including pediatrics, obstetrics, emergency, and ICUs.

Traditional automatic chemiluminescence analyzers are typically larger in size, come with numerous accessories, and are costly, hence they are typically situated only in central or emergency laboratories. The MCL60 integrates the benefits of CLIA technology into a more compact platform, achieving high-accuracy, high-throughput, and miniaturized automatic CLIA testing. It requires minimal lab space and can execute over 70 highly sensitive assays including cardiac, inflammatory, children growth hormones, gastric function, cytokines, glycometabolism, preeclampsia, etc.

Related Links:
RealMind Biotech 
Roche Diagnostics China